InxMed (Shanghai) Co Ltd, a clinical stage biotech company dedicated to developing innovative, individualised medicines with international impact, has dosed its first patient in its Phase Ib clinical trial of IN10018 as monotherapy and in combination with MEKi in the patients either with metastatic uveal melanoma or NRAS mutant metastatic melanoma at The University of Texas M D Anderson Cancer Center, United States, it was reported on Monday.

The company also received approval from the Human Research Ethics Committee (HREC) and acknowledgement from Therapeutic Goods Administration (TGA) in Australia for the same protocol. The product is an orally delivered proprietary focal adhesion kinase inhibitor being developed for the treatment or various types of cancer.

This open label phase Ib trial will include six study sites in the United States and three study sites in Australia, and assess the safety, tolerability, PK and antitumor activities of IN10018 as monotherapy and in combination with Roche's MEK inhibitor, Cobimetinib, in patients with metastatic uveal melanoma and NRAS mutant metastatic melanoma.